The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Investing.com - 在制药巨头诺和诺德公司 (Novo Nordisk) (NYSE: NVO )宣布将终止与该远程医疗公司关于减肥药销售的合作后，Hims & Hers Health (NYSE: HIMS )股价暴跌20%。

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.

It’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...